Aerie Pharmaceuticals Inc. diskutieren
Aerie Pharmaceuticals Inc.
WKN: A1W7RL / Symbol: AERI / Name: Aerie Pharma / Aktie / Biotechnologie & medizinische Forschung / Small Cap /
SecteurRecherche biotechnologique et médicale Agenda 19/09 | 17:55 Présentation
Aerie Pharmaceuticals, Inc. is a clinical stage pharmaceutical company, which engages in the discovery, development, and commercialization of therapies for the treatment of patients with glaucoma and diseases of the eye. Its products include Rhopressa and Roclatan.
The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on June 22, 2005 and is headquartered in Durham, NC.
Nombre d'employés : 160 personnes.
stratec stimmt dem Sentiment von 'Buy' zu
JMP Securities likes Aerie Pharmaceuticals (AERI) today as they reiterate their Buy rating and $80 price target. JMP's analyst believes Q3 revenue will hit $5.4 million, above the $4.8 million consensus. He also believes 'revenue and prescriptions to accelerate in 2019 when Aerie obtains extended Medicare Part D formulary coverage and Roclatan is approved'
Geht's
wieder hoch?
Wiedereinstieg
nach Stoploss.
65$
möglich.
klostergang stimmt dem Crowdsentiment von 'Buy' zu
klostergang stimmt am 21.02.2019 dem Buy-Crowdsentiment mit dem Kursziel 64$ zu.
Boden
erreicht?
Neueste Beiträge
WatchMen in Taseko Mines Ltd diskutieren